metformin has been researched along with Acute Lymphoid Leukemia in 16 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We reviewed patients with acute lymphoblastic leukemia treated with corticosteroids and asparaginase who received metformin for control of hyperglycemia." | 7.79 | Safety and efficacy of metformin for therapy-induced hyperglycemia in children with acute lymphoblastic leukemia. ( Bostrom, B; Chu, J; Gandrud, L; McEvoy, R; Messinger, Y; Uppal, P, 2013) |
| " Hyperglycemia was determined without any clinical sign and metformin was started for steroid-induced insulin resistance." | 3.80 | Metformin-induced hemolytic anemia. ( Arman Bilir, O; Kirkiz, S; Tunc, B; Yarali, N, 2014) |
| "We reviewed patients with acute lymphoblastic leukemia treated with corticosteroids and asparaginase who received metformin for control of hyperglycemia." | 3.79 | Safety and efficacy of metformin for therapy-induced hyperglycemia in children with acute lymphoblastic leukemia. ( Bostrom, B; Chu, J; Gandrud, L; McEvoy, R; Messinger, Y; Uppal, P, 2013) |
| "Metformin was administered twice daily for 28 days in addition to vincristine, dexamethasone, PEG-asparaginase and doxorubicin (VXLD)." | 2.87 | A phase I window, dose escalating and safety trial of metformin in combination with induction chemotherapy in relapsed refractory acute lymphoblastic leukemia: Metformin with induction chemotherapy of vincristine, dexamethasone, PEG-asparaginase, and doxo ( Barredo, JC; Gill, J; Goldberg, J; Hale, GA; Leclerc, GM; Lee, JK; Lush, R; Reed, DR; Setty, B; Smith, T; Trucco, M, 2018) |
| "In acute lymphoblastic leukemia (ALL), high ABCB1 gene expression has been associated with treatment resistance, which affects patient prognosis." | 2.87 | Effect of metformin on the survival of patients with ALL who express high levels of the ABCB1 drug resistance gene. ( Cerón-Maldonado, R; Collazo-Jaloma, J; Kassack-Ipiña, JJ; Martínez-Tovar, A; Meléndez-Mier, G; Olarte-Carrillo, I; Ramos-Peñafiel, C; Rozen-Fuller, E, 2018) |
| "Acute lymphoblastic leukemia (ALL) is one of the most common type of leukemia in children." | 1.62 | Metformin dampens cisplatin cytotoxicity on leukemia cells after incorporation into cubosomal nanoformulation. ( Al-Mahallawi, AM; Saber, MM; Stork, B, 2021) |
| "Metformin has antineoplastic and cancer protective effects in vitro, sensitizing leukemia cells to chemotherapeutic agents, inducing apoptosis and cell cycle arrest." | 1.48 | [Effect of metformin added to chemotherapy on the survival of patients with acute lymphoblastic leukemia]. ( Centeno Cruz, F; Ceron Maldonado, R; Collazo Jaloma, J; Kassack Ipiña, JJ; Martínez Tovar, A; Miranda Peralta, E; Olarte Carrillo, I; Ramos Peñafiel, C; Rozen Fuller, E, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (6.25) | 29.6817 |
| 2010's | 13 (81.25) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Saber, MM | 1 |
| Al-Mahallawi, AM | 1 |
| Stork, B | 1 |
| Zhou, Y | 1 |
| Du, B | 1 |
| Kan, M | 1 |
| Chen, S | 1 |
| Tang, BH | 1 |
| Nie, AQ | 1 |
| Ye, PP | 1 |
| Shi, HY | 1 |
| Hao, GX | 1 |
| Guo, XL | 1 |
| Han, QJ | 1 |
| Zheng, Y | 1 |
| Zhao, W | 1 |
| Trucco, M | 1 |
| Barredo, JC | 2 |
| Goldberg, J | 1 |
| Leclerc, GM | 2 |
| Hale, GA | 1 |
| Gill, J | 1 |
| Setty, B | 1 |
| Smith, T | 1 |
| Lush, R | 1 |
| Lee, JK | 1 |
| Reed, DR | 1 |
| Ramos-Peñafiel, C | 1 |
| Olarte-Carrillo, I | 1 |
| Cerón-Maldonado, R | 1 |
| Rozen-Fuller, E | 1 |
| Kassack-Ipiña, JJ | 1 |
| Meléndez-Mier, G | 1 |
| Collazo-Jaloma, J | 1 |
| Martínez-Tovar, A | 1 |
| Ramos Peñafiel, C | 1 |
| Olarte Carrillo, I | 1 |
| Ceron Maldonado, R | 1 |
| Miranda Peralta, E | 1 |
| Rozen Fuller, E | 1 |
| Kassack Ipiña, JJ | 1 |
| Centeno Cruz, F | 1 |
| Collazo Jaloma, J | 1 |
| Martínez Tovar, A | 1 |
| Bostrom, B | 1 |
| Uppal, P | 1 |
| Chu, J | 1 |
| Messinger, Y | 1 |
| Gandrud, L | 1 |
| McEvoy, R | 1 |
| Leclerc, GJ | 1 |
| Kuznetsov, JN | 1 |
| DeSalvo, J | 1 |
| Kirkiz, S | 1 |
| Yarali, N | 1 |
| Arman Bilir, O | 1 |
| Tunc, B | 1 |
| Mendivil-Perez, M | 1 |
| Jimenez-Del-Rio, M | 1 |
| Velez-Pardo, C | 1 |
| Wang, ES | 1 |
| Wetzler, M | 1 |
| Shi, R | 1 |
| Lin, J | 1 |
| Gong, Y | 1 |
| Yan, T | 1 |
| Shi, F | 1 |
| Yang, X | 1 |
| Liu, X | 1 |
| Naren, D | 1 |
| Vakana, E | 1 |
| Platanias, LC | 1 |
| Vu, K | 1 |
| Busaidy, N | 1 |
| Cabanillas, ME | 1 |
| Konopleva, M | 2 |
| Faderl, S | 1 |
| Thomas, DA | 1 |
| O'Brien, S | 1 |
| Broglio, K | 1 |
| Ensor, J | 1 |
| Escalante, C | 1 |
| Andreeff, M | 2 |
| Kantarjian, H | 1 |
| Lavis, V | 1 |
| Yeung, SC | 2 |
| Pan, J | 1 |
| Chen, C | 1 |
| Jin, Y | 1 |
| Fuentes-Mattei, E | 1 |
| Velazquez-Tores, G | 1 |
| Benito, JM | 1 |
| Lee, MH | 1 |
| Wędrychowicz, A | 1 |
| Ciechanowska, M | 1 |
| Stelmach, M | 1 |
| Starzyk, J | 1 |
| Rooney, DP | 1 |
| Ryan, MF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Metformin on ABCB1 and AMPK Expression in Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia[NCT05326984] | 20 participants (Anticipated) | Interventional | 2021-02-09 | Recruiting | |||
| Effect of the Addition of Metformin Hydrochloride on the Prognosis of Patients With B-cell Precursor (Ph+ Negative) Acute Lymphoblastic Leukemia With High Expression of ABCB1 Gene[NCT03118128] | 102 participants (Actual) | Interventional | 2015-01-01 | Completed | |||
| Efficacy of metfOrmin in PrevenTIng Glucocorticoid-induced Diabetes in Melanoma, breAst or Lung Cancer Patients With Brain Metastases: the Phase II OPTIMAL Study[NCT04001725] | Phase 2 | 110 participants (Anticipated) | Interventional | 2019-10-15 | Recruiting | ||
| Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia[NCT00500240] | Phase 3 | 52 participants (Actual) | Interventional | 2004-04-30 | Terminated (stopped due to Terminated early due to futility.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The overall survival rate defined as percentage of participants in each treatment group who are still alive at 12 months. (NCT00500240)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| Conventional Care | 80.8 |
| Intensive Insulin | 63.5 |
Overall survival (OS) defined as the interval between the date of randomization and the date of death. Calculation of period was from baseline (date of randomization) to the death or last follow-up. (NCT00500240)
Timeframe: Baseline (date of randomization) to date of death or last follow-up (weekly during treatment then every 2 months post study treatment) up to 6 years
| Intervention | Months (Median) |
|---|---|
| Conventional Care | 44 |
| Intervention Group | 62.2 |
PFS was defined as the time interval between the date of complete remission and the date of relapse detection or death. Complete Remission (CR) defined as granulocyte count >1.0 × 10^9/L, platelet count >100 × 10^9/L, no abnormal peripheral blasts, and <5% blasts in normocellular or hypercellular bone marrow. (NCT00500240)
Timeframe: Date of complete remission to disease progression, assessed for approximately 6 years
| Intervention | Months (Median) |
|---|---|
| Conventional Care | 38.8 |
| Intensive Insulin | 24 |
1 review available for metformin and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications.
Topics: AMP-Activated Protein Kinase Kinases; Genes, abl; Hematologic Neoplasms; Humans; Leukemia; Metformin | 2011 |
3 trials available for metformin and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
A phase I window, dose escalating and safety trial of metformin in combination with induction chemotherapy in relapsed refractory acute lymphoblastic leukemia: Metformin with induction chemotherapy of vincristine, dexamethasone, PEG-asparaginase, and doxo
Topics: Adolescent; AMP-Activated Protein Kinases; Antineoplastic Combined Chemotherapy Protocols; Asparagin | 2018 |
Effect of metformin on the survival of patients with ALL who express high levels of the ABCB1 drug resistance gene.
Topics: Adolescent; Adult; ATP Binding Cassette Transporter, Subfamily B; Drug Resistance, Neoplasm; Female; | 2018 |
A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Gl | 2012 |
12 other studies available for metformin and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
Metformin dampens cisplatin cytotoxicity on leukemia cells after incorporation into cubosomal nanoformulation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cisplatin; Dose-Respons | 2021 |
Drug Elimination Alteration in Acute Lymphoblastic Leukemia Mediated by Renal Transporters and Glomerular Filtration.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromatography, High Pressure Liqu | 2020 |
[Effect of metformin added to chemotherapy on the survival of patients with acute lymphoblastic leukemia].
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; D | 2018 |
Safety and efficacy of metformin for therapy-induced hyperglycemia in children with acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Female; Humans; | 2013 |
Metformin induces apoptosis through AMPK-dependent inhibition of UPR signaling in ALL lymphoblasts.
Topics: AMP-Activated Protein Kinases; Apoptosis; Cell Line; Cell Proliferation; Cell Survival; Endoplasmic | 2013 |
Metformin-induced hemolytic anemia.
Topics: Adolescent; Anemia, Hemolytic; Glucosephosphate Dehydrogenase; Hemoglobins; Humans; Hyperglycemia; H | 2014 |
Response to rotenone is glucose-sensitive in a model of human acute lymphoblastic leukemia: involvement of oxidative stress mechanism, DJ-1, Parkin, and PINK-1 proteins.
Topics: Apoptosis; Biomarkers; Caspase 3; Cell Nucleus Shape; Enzyme Activation; Glucose; Humans; Hydrogen P | 2014 |
An oncologist's perspective on metformin use and acute lymphoblastic leukemia outcomes.
Topics: Diabetes Mellitus; Humans; Hypoglycemic Agents; Medical Oncology; Metformin; Precursor Cell Lymphobl | 2015 |
The antileukemia effect of metformin in the Philadelphia chromosome-positive leukemia cell line and patient primary leukemia cell.
Topics: Antineoplastic Agents; Autophagy; Benzamides; Drug Resistance, Neoplasm; Drug Synergism; Humans; Ima | 2015 |
Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells.
Topics: Adolescent; Apoptosis; Cell Line, Tumor; Cell Proliferation; Child; Child, Preschool; Daunorubicin; | 2012 |
Diabetes mellitus after allogeneic hematopoietic stem cell transplantation.
Topics: Adolescent; Comorbidity; Diabetes Mellitus; Drug Therapy, Combination; Female; Graft vs Host Disease | 2013 |
Diabetes with partial lipodystrophy following sclerodermatous chronic graft vs. host disease.
Topics: Adolescent; Bone Marrow Transplantation; Diabetes Mellitus, Type 2; Female; Graft vs Host Disease; H | 2006 |